GLP1R and type 2 diabetes mellitus: However, due to the exciting CVOT data for GLP1-RA and SGLT2i, metformin as first-line medical therapy for T2D patients with ASCVD is now under review because the evidence of cardiovascular benefit appears weak (Harrington et al., 2018).